Pharmasset and Roche announced that the first patient has been dosed in a Phase 2b study of R7128 for the treatment of chronic hepatitis C (HCV). This trial will enroll about 400 treatment-naïve patients with HCV genotypes 1 or 4 at sites worldwide.  The primary efficacy endpoint of the trial will be the proportion of patients who achieve a sustained virological response (SVR), defined as undetectable levels of HCV (measured by Roche TaqMan assay) 24 weeks after completion of treatment. The goal of adding R7128 to existing standard therapy is to improve SVR rates and to shorten the length of treatment for patients.

R7128, a cytidine nucleoside analog inhibitor, has shown to have in vitro activity against all of the most common HCV genotypes.  

For more information call (800) 526-6367 or visit www.rocheusa.com.